SERA - התחייבויות לטווח ארוך להון Sera Prognostics

This price chart for Sera Prognostics (SERA) illustrates the dynamics of a company scaling biomarker systems to predict preterm birth, where the indicator stands at 0.05. The business relies on B2B deals with insurers to capture the diagnostic segment. The project's success is based on the recognition of its tests by medical protocols and the confirmation of their financial benefit for specialized clinics.

The development of innovative PreTRM diagnostics requires significant R&D investment, making the financing structure of Sera Prognostics (SERA) critical for business sustainability. This metric correlates liabilities with a maturity of over one year to equity, measuring the company's degree of dependence on long-term debt capital. Analyzing the long-term debt-to-equity ratio allows for an assessment of the balance between financial leverage and insolvency risk.